CEO MESSAGE

As the global population ages, evidence suggests that hearing loss can contribute to dementia and social isolation.
However, the reality is that most hearing loss lacks specialized treatments, making it one of the most challenging conditions to cure fundamentally.

Researchers at Juntendo University have identified that the most common cause of hereditary hearing loss lies in abnormalities of a molecule called gap junction, which exists in inner ear cells, and have developed a new type of biopharmaceutical targeting these abnormalities.
Gap Junction Therapeutics, Inc. was founded in 2021 to commercialize these hearing loss biopharmaceuticals.
Our company aims to achieve fundamental treatments and prevention for various diseases involving hearing loss and gap junction molecules through initiatives utilizing the latest biotechnology.

CEOKazusaku KAMIYA